These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 34633074)

  • 1. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
    Rosenfeld WE; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Krauss GL; Sperling MR; Vossler DG; Klein P; Wechsler R
    Epilepsia; 2021 Dec; 62(12):3016-3028. PubMed ID: 34633074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
    Sperling MR; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Klein P; Krauss GL; Vossler DG; Wechsler R; Ferrari L; Grall M; Rosenfeld WE
    Epilepsia; 2021 Dec; 62(12):3005-3015. PubMed ID: 34633084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
    Rosenfeld WE; Nisman A; Ferrari L
    Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study.
    O'Dwyer R; Stern S; Wade CT; Guggilam A; Rosenfeld WE
    Drugs Aging; 2024 Mar; 41(3):251-260. PubMed ID: 38446341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency.
    Aboumatar S; Biton V; Wechsler R; Ferrari L; Rosenfeld WE
    Epilepsy Res; 2022 Oct; 186():107014. PubMed ID: 36063589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
    Abou-Khalil B; Aboumatar S; Klein P; Krauss GL; Sperling MR; Rosenfeld WE
    Epilepsy Res; 2022 Aug; 184():106952. PubMed ID: 35671632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study.
    Aboumatar S; Ferrari L; Stern S; Wade CT; Weingarten M; Connor GS; Rosenfeld WE
    Epilepsy Res; 2024 Feb; 200():107306. PubMed ID: 38340681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
    Sperling MR; Klein P; Aboumatar S; Gelfand M; Halford JJ; Krauss GL; Rosenfeld WE; Vossler DG; Wechsler R; Borchert L; Kamin M
    Epilepsia; 2020 Jun; 61(6):1099-1108. PubMed ID: 32396252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
    Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V
    Epilepsia Open; 2024 Jun; 9(3):1051-1058. PubMed ID: 38573131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications.
    Brandt C; Sánchez-Álvarez JC; Steinhoff BJ; Milanov I; Serratosa JM
    Seizure; 2022 Mar; 96():86-93. PubMed ID: 35168142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study.
    French JA; Chung SS; Krauss GL; Lee SK; Maciejowski M; Rosenfeld WE; Sperling MR; Kamin M
    Epilepsia; 2021 Sep; 62(9):2142-2150. PubMed ID: 34254673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study.
    Rosenfeld WE; Ferrari L; Kamin M
    Epilepsy Res; 2022 Jul; 183():106940. PubMed ID: 35605481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures.
    Privitera M; Richy FF; Schabert VF
    Epilepsy Behav; 2022 Jan; 126():108429. PubMed ID: 34864380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations.
    Smith MC; Klein P; Krauss GL; Rashid S; Seiden LG; Stern JM; Rosenfeld WE
    Neurol Ther; 2022 Dec; 11(4):1705-1720. PubMed ID: 36057761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study.
    Serrano-Castro PJ; Ramírez-García T; Cabezudo-Garcia P; Garcia-Martin G; De La Parra J
    CNS Drugs; 2024 Feb; 38(2):141-151. PubMed ID: 38265735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cenobamate add-on therapy for drug-resistant focal epilepsy.
    Brigo F; Lattanzi S
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014941. PubMed ID: 39087564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of efficacy and adverse events during Cenobamate titration period.
    Steinhoff BJ; Ben-Menachem E; Brandt C; García Morales I; Rosenfeld WE; Santamarina E; Serratosa JM
    Acta Neurol Scand; 2022 Sep; 146(3):265-275. PubMed ID: 35711112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain.
    Rodríguez-Uranga JJ; Sánchez-Caro JM; Hariramani Ramchandani R
    Epilepsia Open; 2024 Aug; 9(4):1345-1356. PubMed ID: 38800945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive cenobamate based on patient etiology: Post-hoc analysis of YKP3089C017 randomized clinical trial.
    Xu J; Wei W; Liu Y; Ye H; Liu X
    Seizure; 2024 May; 118():95-102. PubMed ID: 38652999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam.
    Steinhoff BJ; Georgiou D; Intravooth T
    Epilepsia Open; 2024 Aug; 9(4):1502-1514. PubMed ID: 38861254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.